Sanofi-Maze deal abandonment a 'big win for patients,' US FTC says
MLex Summary: Sanofi and Maze's decision to walk away from their licensing agreement following the US Federal Trade Commission's suit to block the deal on Monday is a "big win for...To view the full article, register now.
Already a subscriber? Click here to view full article